Literature DB >> 11248693

Generation of human high-affinity antibodies specific for the fibroblast activation protein by guided selection.

A Schmidt1, D Müller, M Mersmann, T Wüest, E Gerlach, P Garin-Chesa, W J Rettig, K Pfizenmaier, D Moosmayer.   

Abstract

Four completely human antibody derivatives [single-chain-antibody fragments (scFvs)] with specificity for the general tumor stroma marker fibroblast activation protein (FAP) were isolated by guided selection. Highly diverse IgG, IgM and IgD isotypes comprising heavy-chain variable domain libraries were generated using cDNAs derived from diverse lymphoid organs of a multitude of donors. Three of the human scFvs were converted into bivalent minibodies and expressed in eukaryotic cells for further functional characterization. Binding-competition studies and analysis by fluorescence-activated cell sorting showed high-affinity binding (10--20 nM) for two clones and recognition of the same epitope as the murine guiding antibody. The minibodies were successfully used for immunohistology of a variety of human carcinoma biopsies, revealing specific staining of stromal fibroblasts. Therefore, they should be suitable for in vivo diagnostic and tumor-targeting studies and, because of their completely human origin, be superior to murine or humanized antibody derivatives.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11248693

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  7 in total

1.  Conversion of a murine monoclonal antibody A13 targeting epidermal growth factor receptor to a human monoclonal antibody by guided selection.

Authors:  Ki Hwan Chang; Min Soo Kim; Gwang Won Hong; Yong Nam Shin; Se Ho Kim
Journal:  Exp Mol Med       Date:  2012-01-31       Impact factor: 8.718

2.  Effect of fibroblast activation protein and alpha2-antiplasmin cleaving enzyme on collagen types I, III, and IV.

Authors:  Victoria J Christiansen; Kenneth W Jackson; Kyung N Lee; Patrick A McKee
Journal:  Arch Biochem Biophys       Date:  2006-11-17       Impact factor: 4.013

3.  Fibroblast activation protein α activatable theranostic pro-photosensitizer for accurate tumor imaging and highly-specific photodynamic therapy.

Authors:  Yong Luo; Zishan Zeng; Ting Shan; Xiaoyu Xu; Jie Chen; Yuanfeng He; Tao Zhang; Zeqian Huang; Guihong Chai; Yanjuan Huang; Yanfang Zhao; Chunshun Zhao
Journal:  Theranostics       Date:  2022-05-01       Impact factor: 11.600

4.  Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients.

Authors:  C Kloft; E-U Graefe; P Tanswell; A M Scott; R Hofheinz; A Amelsberg; M O Karlsson
Journal:  Invest New Drugs       Date:  2004-01       Impact factor: 3.850

5.  Phage display on the base of filamentous bacteriophages: application for recombinant antibodies selection.

Authors:  N V Tikunova; V V Morozova
Journal:  Acta Naturae       Date:  2009-10       Impact factor: 1.845

Review 6.  The application of the fibroblast activation protein α-targeted immunotherapy strategy.

Authors:  Guan-Min Jiang; Wei Xu; Jun Du; Kun-Shui Zhang; Qiu-Gui Zhang; Xiao-Wei Wang; Zhi-Gang Liu; Shuang-Quan Liu; Wan-Ying Xie; Hui-Fang Liu; Jing-Shi Liu; Bai-Ping Wu
Journal:  Oncotarget       Date:  2016-05-31

7.  Automated Radiosynthesis, Preliminary In Vitro/In Vivo Characterization of OncoFAP-Based Radiopharmaceuticals for Cancer Imaging and Therapy.

Authors:  Francesco Bartoli; Philip Elsinga; Luiza Reali Nazario; Aureliano Zana; Andrea Galbiati; Jacopo Millul; Francesca Migliorini; Samuele Cazzamalli; Dario Neri; Riemer H J A Slart; Paola Anna Erba
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.